Prognostic impact of lymphocytes in soft tissue Sarcomas

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Sorbye, Sveinung W ^a,b   Kilvaer, Thomas ^b   Valkov, Andrej ^a,b   Donnem, Tom ^a,b   Smeland, Eivind ^a   Al Shibli, Khalid ^b,c   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CD20+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD45+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRESCHOOL CHILD; PROGNOSIS; SCHOOL CHILD; SOFT TISSUE SARCOMA; T LYMPHOCYTE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; PATHOLOGY; SARCOMA; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD; ANTIGENS, CD20; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS; SARCOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551518508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014611     Document Type: Article

References (43)

1. Gustafson P (1994) Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259: 1-31.
2. Engellau J, Anderson H, Rydholm A, Bauer HC, Hall KS, et al. (2004) Time dependence of prognostic factors for patients with soft tissue sarcoma: aScandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Cancer 100: 2233-2239.
3. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, et al. (2006) Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg 76: 104-109.
4. Kiatisevi P, Asavamongkolkul A, Phimolsarnti R, Waikakul S, Benjarassamerote S (2006) The outcomes and prognostic factors of patients with softtissue sarcoma. J Med Assoc Thai 89: 334-342.
5. Koea JB, Leung D, Lewis JJ, Brennan MF (2003) Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol 10: 432-440.
6. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, et al. (2005) Retroperitoneal soft tissue sarcoma. Cancer 104: 669-675.
7. Raney RB, Jr., Crist WM, Maurer HM, Foulkes MA (1983) Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I.Cancer 52: 44-50.
8. Yang RS, Lane JM, Eilber FR, Dorey FJ, al Shaikh R, et al. (1995) High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis. Cancer 76: 1398-1405.
9. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, et al. (2003) Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57: 739-747.
10. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, et al. (2005) Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25: 4519-4526.
11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
12. Nocito A, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 94: 1-5.
13. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662.
14. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
15. Mukai S, Kjaergaard J, Shu S, Plautz GE (1999) Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 59: 5245-5249.
16. Costello RT, Gastaut JA, Olive D (1999) Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 47: 83-88.
17. Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding-Jarbrink M (2007) CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur J Immunol 37: 282-291.
18. Gimotty PA, Zhang L, Alagkiozidis I, Cadungog M, Adams S, et al. (2007) Immune prognostic factors in ovarian cancer: lessons from translational research. Dis Markers 23: 445-452.
19. Nelson BH (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222: 101-116.
20. Raspollini MR, Castiglione F, Rossi DD, Amunni G, Villanucci A, et al. (2005) Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 16: 590-596.
21. Tomsova M, Melichar B, Sedlakova I, Steiner I (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108: 415-420.
22. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
23. Denkert C, Loibl S, Noske A, Roller M, Muller BM, et al. (2010) Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113.
24. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, et al. (2009) Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137: 1270-1279.
25. Ancuta E, Ancuta C, Zugun-Eloae F, Iordache C, Chirieac R, et al. (2009) Predictive value of cellular immune response in cervical cancer. Rom J Morphol Embryol 50: 651-655.
26. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, et al. (2006) NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125: 451-458.
27. Hong C, Lee H, Oh M, Kang CY, Hong S, et al. (2006) CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT celldependent tumor rejection. J Immunol 177: 6747-6757.
28. Al Shibli KI, Donnem T, Al Saad S, Persson M, Bremnes RM, et al. (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14: 5220-5227.
29. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, et al. (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94: 275-280.
30. Eerola AK, Soini Y, Paakko P (2000) A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and afavorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6: 1875-1881.
31. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB (2004) Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10: 4450-4456.
32. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, et al. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494.
33. Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, et al. (2003) Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 84: 224-228.
34. Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932-3936.
35. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, et al. (2007) CD8 tumorinfiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104: 3967-3972.
36. Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, et al. (2006) Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol 19: 171-179.
37. Wahlin BE, Sander B, Christensson B, Kimby E (2007) CD8+ T-cell content in iagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 13: 388-397.
38. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, et al. (2005) Tumourinfiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 25: 4435-4438.
39. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, et al. (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4: e6412.
40. Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE (2001) Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 44: 180-188.
41. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, et al. (2009) Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 9: 292.
42. Thornton K (2008) Chemotherapeutic management of soft tissue sarcoma. Surg Clin North Am 88: 647-60+viii.
43. Sikora K, Alderson T, Ellis J, Phillips J, Watson J (1983) Human hybridomas from patients with malignant disease. Br J Cancer 47: 135-145.